Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
SGLT2 inhibitor |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2014 |
| gptkbp:ATCCode |
A10BK03
|
| gptkbp:brand |
gptkb:Jardiance
|
| gptkbp:CASNumber |
864070-44-0
|
| gptkbp:combines |
gptkb:metformin
linagliptin |
| gptkbp:contraindication |
type 1 diabetes
severe renal impairment |
| gptkbp:developedBy |
gptkb:Boehringer_Ingelheim
gptkb:Eli_Lilly_and_Company |
| gptkbp:eliminationHalfLife |
12.4 hours
|
| gptkbp:hasMolecularFormula |
C23H27ClO7
|
| https://www.w3.org/2000/01/rdf-schema#label |
empagliflozin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits sodium-glucose co-transporter 2
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:proteinBinding |
86.2%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
urinary tract infection
hypotension genital infection ketoacidosis |
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
heart failure |
| gptkbp:bfsParent |
gptkb:SGLT2_inhibitors
|
| gptkbp:bfsLayer |
6
|